Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma
- PMID: 4987170
- PMCID: PMC322579
- DOI: 10.1172/JCI106327
Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma
Abstract
Studies of synthesis of IgG paraproteins were performed in 10 patients who had IgG myeloma in order to quantitate cellular immunosynthetic functions and derive estimates of the number of tumor cells present in such patients. Serial in vitro studies demonstrated constancy in the cellular rate of IgG paraprotein secretion for up to 8 months. Average molecular synthesis rates in different patients ranged from 12,500 to 85,000 molecules of IgG per minute per myeloma cell. Estimated total body tumor cell number ranged from 0.5 x 10(12) to 3.1 x 10(12) myeloma cells, and could be correlated with the degree of skeletal damage observed on roentgenograms (P = <0.01). Serial measurements of tumor cell number may prove useful in characterizing the growth rate and natural history of multiple myeloma. Myeloma is the first metastatic human malignancy in which quantitative measurements of the body's burden of malignant cells have been obtained.
Similar articles
-
Biosynthesis of immunoglobulin in human immunoproliferative diseases. II. Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with that calculated from clinical staging systems.Acta Haematol. 1982;68(3):224-36. doi: 10.1159/000206985. Acta Haematol. 1982. PMID: 6814151
-
Metabolic properties of IgG subclasses in man.J Clin Invest. 1970 Apr;49(4):673-80. doi: 10.1172/JCI106279. J Clin Invest. 1970. PMID: 5443170 Free PMC article.
-
A human IgG myeloma protein with anti- 2 macroglobulin antibody activity.J Immunol. 1973 Jan;110(1):85-90. J Immunol. 1973. PMID: 4631075 No abstract available.
-
Studies on IgA and IgG monoclonal proteins derived from a single patient. I. Evidence for shared individually specific antigenic determinants.J Immunol. 1974 Jan;112(1):201-9. J Immunol. 1974. PMID: 4130147 No abstract available.
-
Glycosylation of polyclonal and paraprotein IgG in multiple myeloma.Glycoconj J. 1997 Jun;14(4):489-92. doi: 10.1023/a:1018555619519. Glycoconj J. 1997. PMID: 9249147
Cited by
-
[The beginning plasmacytoma].Blut. 1974 Feb;28(2):136-40. doi: 10.1007/BF01634378. Blut. 1974. PMID: 4812251 German. No abstract available.
-
Primary bioassay of human myeloma stem cells.J Clin Invest. 1977 Oct;60(4):846-54. doi: 10.1172/JCI108839. J Clin Invest. 1977. PMID: 302265 Free PMC article.
-
Solitary plasmacytoma of the clavicle.Proc R Soc Med. 1974 Nov;67(11):1097-8. doi: 10.1177/003591577406701103. Proc R Soc Med. 1974. PMID: 4140518 Free PMC article. No abstract available.
-
Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.Curr Oncol Rep. 2017 Aug 12;19(10):66. doi: 10.1007/s11912-017-0625-2. Curr Oncol Rep. 2017. PMID: 28803390 Review.
-
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.Sci Adv. 2022 Sep 30;8(39):eabq5575. doi: 10.1126/sciadv.abq5575. Epub 2022 Sep 28. Sci Adv. 2022. PMID: 36170375 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources